| related words |
| outlicense |
| variant |
| aflibercept |
| liquefied |
| nsclc |
| oreign |
| merlin |
| mafs |
| advair |
| comparator |
| sseldorf |
| biosimilars |
| valopicitabine |
| influencers |
| beam |
| electromechanical |
| eculizumab |
| superseded |
| imi |
| pharmacogenetic |
|
| related documents |
| 1036968--5/31/2007--VAXGEN_INC |
| 1036968--2/7/2007--VAXGEN_INC |
|
| related topics |
| {product, candidate, development} |
| {loss, insurance, financial} |
| {customer, product, revenue} |
| {product, liability, claim} |
| {capital, credit, financial} |
| {provision, law, control} |
| {property, intellectual, protect} |
| {cost, contract, operation} |
| {system, service, information} |
| {loan, real, estate} |
| {stock, price, operating} |
| {personnel, key, retain} |
| {condition, economic, financial} |
| {debt, indebtedness, cash} |
| {tax, income, asset} |
| {cost, operation, labor} |
| {competitive, industry, competition} |
| {financial, litigation, operation} |
| {control, financial, internal} |
| {regulation, government, change} |
|